Established and emerging prognostic factors in mycosis fungoides and Sézary syndrome
-
By
-
Viviane Liao
-
Robert N. Stuver
-
Shamir Geller
-
July 1, 2026
-
Clinical Scorecard: Prognostic Indicators in Mycosis Fungoides and Sézary Syndrome: Established and Novel Insights
At a Glance
| Category | Detail |
|---|
| Condition | Mycosis Fungoides and Sézary Syndrome |
| Key Mechanisms | Malignant transformation of skin-resident T cells and blood involvement. |
| Target Population | Patients with cutaneous T-cell lymphoma (CTCL), specifically MF and SS. |
| Care Setting | Oncology and dermatology clinics specializing in lymphomas. |
Key Highlights
- MF is characterized by an indolent course; SS is more aggressive with significant blood involvement.
- Stage remains the most established prognostic factor in MF/SS.
- Recent genomic advances provide insights into prognostic factors.
- Blood stage classification has been updated to improve prognostic accuracy.
- Integration of traditional and biological prognostic frameworks is emphasized.
Guideline-Based Recommendations
Diagnosis
- Utilize TNMB classification for staging MF/SS.
- Employ clonality assessment for accurate disease compartment classification.
Management
- Focus on symptom control and minimizing treatment-related side effects.
- Consider individualized treatment strategies based on prognostic factors.
Monitoring & Follow-up
- Regular assessment of disease stage and blood involvement.
Risks
- Higher TNMB classification is associated with reduced survival.
Patient & Prescribing Data
Patients with varying stages of MF and SS.
Recent therapies may improve disease-specific survival, but long-term impacts are still being evaluated.
Clinical Best Practices
- Adhere to ISCL/EORTC guidelines for staging and management.
- Consider the impact of genomic alterations on prognosis.
Related Resources & Content
